Abstract Aims Interleukin-6 (IL-6) contributes to atherosclerotic plaque destabilization and is
involved in myocardial injury during ischaemia–reperfusion. Interleukin-6 is therefore a …

Background We recently showed that interleukin (IL)-6 inhibition by tocilizumab improves
myocardial salvage in ST-elevation myocardial infarction (STEMI). However, the …

Background Prompt myocardial revascularization with percutaneous coronary intervention
(PCI) reduces infarct size and improves outcomes in patients with ST-segment elevation …

Background—Convincing evidence suggests that atherosclerosis is an inflammatory
disease. The inflammatory response is an important determinant of atherosclerotic plaque …

Background Anakinra, an interleukin-1 receptor antagonist and tocilizumab, an interleukin-6
receptor blocker, are used for the treatment of rheumatoid arthritis. We investigated the …

Background Interleukin‐6 (IL‐6) is an inflammatory cytokine implicated in plaque instability
in acute coronary syndrome (ACS). We aimed to evaluate the prognostic implications of IL‐6 …

Background Atherosclerosis is a chronic inflammatory disease, with interleukin 6 (IL‐6) as a
major player in inflammation cascade. IL‐6 blockade may reduce cardiovascular risk, but …

Background and aims Myocardial infarction triggers an inflammatory response involved in
cardiac repair. We studied the association of the interleukin 6 (IL-6) cascade with infarct size …

Abstract Aims Acute coronary syndromes (ACSs) are driven by inflammation within coronary
plaque. Interleukin-1 (IL-1) has an established role in atherogenesis and the vessel …

Background Proinflammatory cytokines play a role in acute coronary events. However, the
potential role of antiinflammatory cytokines in the modulation of the atherosclerotic process …